Wednesday, May 05, 2010 12:28:56 PM
AMAG Pharmaceuticals shares fall following lower-than-expected 1st-quarter results
On Wednesday April 28, 2010, 2:06 pm EDT
NEW YORK (AP) -- Shares of AMAG Pharmaceuticals Inc. fell Wednesday after the biotechnology company reported a wider first-quarter loss and weaker revenue than Wall Street expected.
The stock shed $3.42, or 9.3 percent, to $33.36 in afternoon trading. Shares earlier reached a 52-week low of $31.90. They have ranged from $33.11 to $58.23 over the past year.
On Tuesday, the company said it lost $23.1 million, or $1.15 per share, on revenue of $13.3 million during the quarter. Analysts polled by Thomson Reuters, on average, had forecast a loss of 85 cents per share on revenue of $16.8 million.
The bulk of the company's revenue comes from Feraheme, which treats iron deficiency anemia in chronic kidney disease patients.
Jefferies & Co. analyst Eun K. Yang reaffirmed a "Hold" rating on the stock with a $32 price target, citing the lower-than-expected Feraheme sales and wider-than-expected first-quarter loss.
"While its potential in non-dialysis remains, disappointing first-quarter sales suggests challenges it (Feraheme) faces in the competitive, pricing-sensitive intravenous iron market, with little advantages," Yang wrote in a note to investors.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM